{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:59:37Z","timestamp":1766530777836,"version":"3.41.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/tpj.2017.40","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T10:04:43Z","timestamp":1501581883000},"page":"460-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1"],"prefix":"10.1038","volume":"18","author":[{"given":"H-B","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-Z","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-L","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-L","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-Y","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z-W","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-D","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"BFtpj201740_CR1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","volume":"385","author":"E Buchdunger","year":"2002","unstructured":"Buchdunger E, O'Reilly T, Wood J . Pharmacology of imatinib (STI571). Eur J Cancer 2002; 385: S28\u2013S36.","journal-title":"Eur J Cancer"},{"key":"BFtpj201740_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/02841860903287205","volume":"49","author":"P Wolter","year":"2010","unstructured":"Wolter P, Schoffski P . Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. ACTA ONCOL 2010; 49: 13\u201323.","journal-title":"ACTA ONCOL"},{"key":"BFtpj201740_CR3","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236\u20134243.","journal-title":"Cancer Res"},{"key":"BFtpj201740_CR4","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","volume":"90","author":"M Carroll","year":"1997","unstructured":"Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947\u20134952.","journal-title":"Blood"},{"key":"BFtpj201740_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139\u2013145.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201740_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A . Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493\u2013502.","journal-title":"Nat Rev Drug Discov"},{"key":"BFtpj201740_CR7","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496\u20133499.","journal-title":"Blood"},{"key":"BFtpj201740_CR8","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141\u20133147.","journal-title":"J Clin Oncol"},{"key":"BFtpj201740_CR9","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022\u20134028.","journal-title":"Blood"},{"key":"BFtpj201740_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/jhg.2013.42","volume":"58","author":"DL Hertz","year":"2013","unstructured":"Hertz DL, McLeod HL . Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013; 58: 346\u2013352.","journal-title":"J Hum Genet"},{"key":"BFtpj201740_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/17425255.2016.1184649","volume":"12","author":"G Ravegnini","year":"2016","unstructured":"Ravegnini G, Sammarini G, Angelini S, Hrelia P . Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Exp Opin Drug Metab Toxicol 2016; 12: 733\u2013742.","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"BFtpj201740_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cbi.2014.06.009","volume":"219","author":"P Kosztyu","year":"2014","unstructured":"Kosztyu P, Bukvova R, Dolezel P, Mlejnek P . Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem Biol Interact 2014; 219: 203\u2013210.","journal-title":"Chem Biol Interact"},{"key":"BFtpj201740_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.leu.2404897","volume":"22","author":"S Shukla","year":"2008","unstructured":"Shukla S, Sauna ZE, Ambudkar SV . Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008; 22: 445\u2013447.","journal-title":"Leukemia"},{"key":"BFtpj201740_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","volume":"68","author":"S Angelini","year":"2013","unstructured":"Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res 2013; 68: 1\u20136.","journal-title":"Pharmacol Res"},{"key":"BFtpj201740_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin L, Yee SW, Kim RB, Giacomini KM . SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 2015; 14: 543\u2013560.","journal-title":"Nat Rev Drug Discov"},{"key":"BFtpj201740_CR16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/leu.2013.13","volume":"27","author":"S Bouchet","year":"2013","unstructured":"Bouchet S, Dulucq S, Pasquet J, Lagarde V, Molimard M, Mahon F . From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome. LEUKEMIA 2013; 27: 1757\u20131759.","journal-title":"LEUKEMIA"},{"key":"BFtpj201740_CR17","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang LH, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739\u20133745.","journal-title":"Blood"},{"key":"BFtpj201740_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201740_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/10428190701858823","volume":"49","author":"RE Clark","year":"2008","unstructured":"Clark RE, Davies A, Pirmohamed M, Giannoudis A . Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leukemia Lymphoma 2008; 49: 639\u2013642.","journal-title":"Leukemia Lymphoma"},{"key":"BFtpj201740_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193\u2013200.","journal-title":"Haematologica"},{"key":"BFtpj201740_CR21","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1007\/s12032-012-0308-7","volume":"29","author":"J Gao","year":"2012","unstructured":"Gao J, Dang Y, Sun N, Li J, Shen L . C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med Oncol 2012; 29: 3039\u20133045.","journal-title":"Med Oncol"},{"key":"BFtpj201740_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472\u2013480.","journal-title":"N Engl J Med"},{"key":"BFtpj201740_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/108076803322279426","volume":"19","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J . Ocular side-effects associated with imatinib mesylate. J Ocul Pharmacol Ther 2003; 19: 371\u2013375.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFtpj201740_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","volume":"91","author":"WL Ho","year":"2013","unstructured":"Ho WL, Wong H, Yau T . The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 2013; 91: 604\u2013609.","journal-title":"Acta Ophthalmol"},{"key":"BFtpj201740_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/FPC.0b013e3283655091","volume":"23","author":"U Hodoglugil","year":"2013","unstructured":"Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell RC, Altman RB et al. PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenet Genom 2013; 23: 636\u2013642.","journal-title":"Pharmacogenet Genom"},{"key":"BFtpj201740_CR26","first-page":"e852452","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS ONE 2014; 9: e852452.","journal-title":"PLoS ONE"},{"key":"BFtpj201740_CR27","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497\u20131500.","journal-title":"Science"},{"key":"BFtpj201740_CR28","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Koehne C, Hitre E, Zaluski J, Chien CC, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 360: 1408\u20131417.","journal-title":"New Engl J Med"},{"key":"BFtpj201740_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H et al. Cetuximab for the treatment of colorectal cancer. New Engl J Med 2007; 357: 2040\u20132048.","journal-title":"New Engl J Med"},{"key":"BFtpj201740_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/pgs.12.54","volume":"13","author":"C Mayo","year":"2012","unstructured":"Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, Costa C, Rosell R . Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics 2012; 13: 789\u2013802.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201740_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ctrv.2012.09.001","volume":"39","author":"A Rossi","year":"2013","unstructured":"Rossi A, Pasquale R, Esposito C, Normanno N . Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev 2013; 39: 489\u2013497.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201740_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFtpj201740_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341\u2013354.","journal-title":"Nat Rev Cancer"},{"key":"BFtpj201740_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127\u2013137.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFtpj201740_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013; 121: 628\u2013637.","journal-title":"Blood"},{"key":"BFtpj201740_CR36","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DHD Kim","year":"2009","unstructured":"Kim DHD, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750\u20134758.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201740_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Di Paolo","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M, Cervetti G, Barate C, Angelini S et al. The c.480C&gt;G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenom J 2014; 14: 328\u2013335.","journal-title":"Pharmacogenom J"},{"key":"BFtpj201740_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","volume":"24","author":"H Koepsell","year":"2007","unstructured":"Koepsell H, Lips K, Volk C . Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res-Dordr 2007; 24: 1227\u20131251.","journal-title":"Pharm Res-Dordr"},{"key":"BFtpj201740_CR39","doi-asserted-by":"publisher","first-page":"20378","DOI":"10.1074\/jbc.273.32.20378","volume":"273","author":"I Tamai","year":"1998","unstructured":"Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998; 273: 20378\u201320382.","journal-title":"J Biol Chem"},{"key":"BFtpj201740_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ajmg.c.30087","volume":"142C","author":"N Longo","year":"2006","unstructured":"Longo N, Filippo C, Pasquali M . Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C 2006; 142C: 77\u201385.","journal-title":"Am J Med Genet C"},{"key":"BFtpj201740_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3","volume":"15","author":"YH Wang","year":"2000","unstructured":"Wang YH, Kelly MA, Cowan TM, Longo N . A missense mutation in the OCTN2 gene associated with residual carnitine transport activity. Hum Mutat 2000; 15: 238\u2013245.","journal-title":"Hum Mutat"},{"key":"BFtpj201740_CR42","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735\u20137738.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201740_CR43","doi-asserted-by":"crossref","first-page":"20383","DOI":"10.1016\/S0021-9258(19)88713-6","volume":"267","author":"T Tatsuta","year":"1992","unstructured":"Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T . Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383\u201320391.","journal-title":"J Biol Chem"},{"key":"BFtpj201740_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT . Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 2015; 54: 709\u2013735.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201740_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/tpj.2016.31","volume":"17","author":"Y Ma","year":"2017","unstructured":"Ma Y, Xin S, Huang M, Yang Y, Zhu C, Zhao H et al. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J 2017; 17: 325\u2013330.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201740_CR46","first-page":"2929","volume":"61","author":"K Pietras","year":"2001","unstructured":"Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929\u20132934.","journal-title":"Cancer Res"},{"key":"BFtpj201740_CR47","first-page":"881","volume":"95","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer-Am Cancer Soc 2002; 95: 881\u2013887.","journal-title":"Cancer-Am Cancer Soc"},{"key":"BFtpj201740_CR48","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.leukres.2004.03.007","volume":"28","author":"P Bruck","year":"2004","unstructured":"Bruck P, Wassmann B, Lopez ER, Hoelzer D, Ottmann OG . Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leukemia Res 2004; 28: 1153\u20131157.","journal-title":"Leukemia Res"},{"key":"BFtpj201740_CR49","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1200\/JCO.2010.31.9236","volume":"29","author":"S Postel-Vinay","year":"2011","unstructured":"Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 2011; 29: 1728\u20131735.","journal-title":"J Clin Oncol"},{"key":"BFtpj201740_CR50","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","volume":"50","author":"S Postel-Vinay","year":"2014","unstructured":"Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents\u2013Dose-limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted Therapies, An European Organisation For Research and Treatment of Cancer-led Study. Eur J Cancer 2014; 50: 2040\u20132049.","journal-title":"Eur J Cancer"},{"issue":"8","key":"BFtpj201740_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrclinonc.2010.9-c1","volume":"7","author":"Andr\u00e9s J. M. Ferreri","year":"2010","unstructured":"Ferreri AJM, Illerhaus G, Zucca E, Cavalli F . Flows and flaws in primary central nervous system lymphoma. Nat Rev Clin Oncol 2010; 7: 10-1038, 10-1038.","journal-title":"Nature Reviews Clinical Oncology"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201740","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2017.40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:34:10Z","timestamp":1750793650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFtpj201740"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2017.40","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2017,8,1]]},"assertion":[{"value":"18 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}